DarioHealth Corp.
Close on Oct 19, 2026
- Market cap
- $41.95M
- P/E (TTM)
- 1.1
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2023 Ended Jun 30, 2023 | Jul 24, 2023 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Feb 6, 2023 | Before market open | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 15, 2022 | Before market open | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Jan 19, 2022 | Before market open | – | – | – |
| Q2 FY2021 Ended Jun 30, 2021 | Aug 16, 2021 | Before market open | – | – | – |
Press releases
Announcements DarioHealth filed with the SEC
of a $23.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Material agreement · Other events · EX-99.1 to Form 8-K
Veteran Healthcare Executive John R. Palumbo to Board of
Executive or director change · Other events · EX-99.1 to Form 8-K
DarioHealth Announces $17.5 Million Private
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
DarioHealth Announces 20-to-1 Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
DarioHealth Appoints Healthcare Industry Leader
Executive or director change · Other events · EX-99.1 to Form 8-K
$25.6M Private Placement Positioning the Company to Execute on
Other events · EX-99.1 to Form 8-K
This presentation of DarioHealth Corp. (“Dario”, the “Company”, “we” and “our”) and
Regulation FD disclosure · EX-99.1 to Form 8-K
This presentation of DarioHealth Corp. (“Dario”, the “Company”, “we” and “our”) and
Material agreement · New financial obligation · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Dario acquires Twill creating one of the most
Material agreement · New financial obligation · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Nasdaq | DRIO | October 17th, 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
Dario Launches Agreement with Large
Results of operations · Other events · EX-99.1 to Form 8-K
convertible preferred stock priced at the market under Nasdaq rules with significant participation by select members of leadership, the
Material agreement · Agreement terminated · New financial obligation · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Dario Appoints Industry Veteran Jon Kaplan to
Executive or director change · Other events · EX-99.1 to Form 8-K
DARIOHEALTH ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2022 OPERATING RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
16 16 Strategic approach to partnership accelerates commercial adoption and enhances competitiveness Mature Partners Select Dario to Accelerate Digitalization
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
DarioHealth Reports Second Quarter 2022 Financial
Results of operations · EX-99.1 to Form 8-K
2 *Business to Business to Consumer
Results of operations · EX-99.2 to Form 8-K
DarioHealth Secures $50 Million Dollar Non-Dilutive Credit Facility
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
DarioHealth Enters into Strategic Agreement
Material agreement · Other events · EX-99.1 to Form 8-K
DarioHealth (NASDAQ: DRIO) Webinar: 3 Navigating Emerging Digital Health Trends for Strategic Growth in 2022
Material agreement · Results of operations · EX-99.1 to Form 8-K
DarioHealth to Host Investor Webinar on Navigating
Material agreement · Results of operations · EX-99.2 to Form 8-K